WealthStone’s Core Laboratories CLB Stock Holding History

WealthStone’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,880	Closed	-$569K	–	169
2019 Q2	$569K	Buy	+10,880	New	+$638K	0.26%	79

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

WealthStone's CLB Position: Q3 2019 in Review

WealthStone sold out of Core Laboratories (CLB) in Q3 2019, closing a stake of 10,880 shares — an estimated $569K sold.

WealthStone first reported a position in CLB in Q2 2019 and held it in 1 quarter. The position peaked at $569K in Q2 2019. 274 funds tracked by Wall St. Rank hold CLB as of Q3 2019.

WealthStone reported no remaining Core Laboratories position as of Q3 2019 after selling out during the quarter.
WealthStone sold 10,880 Core Laboratories shares in Q3 2019, an estimated $569K.
WealthStone first reported a position in Core Laboratories in Q2 2019 and held it in 1 quarter.
WealthStone's Core Laboratories position peaked at $569K in Q2 2019.
274 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2019.

Based on WealthStone's 13F filing for Q3 2019, filed 15 Nov 2019.